Dean Rudge on Muck Rack

Dean Rudge

Verified
Birmingham
As seen in: Generics Bulletin, Wales on Sunday, Manchester Evening News, Rochdale Observer, Birmingham Mail, Liverpool Echo, The Chronicle, Coventry Live, Bristol Post, Hull Daily Mail, Nottingham Post and
Assistant editor at Generics bulletin
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Dean

Contact Dean, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Xbrane Bets On Partners To Unlock Darzalex Biosimilar

|
By Dean Rudge 
| Generics Bulletin
JOINN Biologics Partnership Pushes Daratumumab Biosimilar Forward Without Fresh Spending Xbrane has partnered with JOINN Biologics US to advance Xdarzane, its proposed Darzalex biosimilar, shifting further CMC and pilot-scale work to a specialist manufacturer as the Swedish developer pursues a capital-light strategy built around partnerships, licensing and retained upside.
Open in Who Shared Issue with article?

Streamlining Alone Will Not Fill Europe’s Biosimilar Void

|
By Dean Rudge 
| Generics Bulletin
Stable IP, Sustainable Procurement And A Stronger Biotech Act Will Determine Future Patient Outcomes Representatives from Medicines for Europe and its Biosimilar Medicines Group tell Generics Bulletin that Europe’s move away from routine comparative efficacy studies is a major step forward but not enough on its own to solve the looming biosimilar “void.” Source: Medicines for Europe Key Takeaways Regulatory streamlining is a major scientific and practical advance, but development decisions...
Open in Who Shared Issue with article?

Apotex Upsizes IPO As Investors Back Canadian Pharma

|
By Dean Rudge 
| Generics Bulletin
Increased Planned Initial Public Offering To Around C$1.3bn, While Retaining Its C$20-C$24 Per-Share Price Range Apotex has upsized its planned TSX IPO to around C$1.3bn, with the listing set to become the exchange’s largest-ever life sciences float while giving existing shareholders a partial exit and leaving SK Capital firmly in control.
Open in Who Shared Issue with article?
See all 1,059 licensed articles (1,533 Total)

Actions

Share this page

Get in touch with Dean

Contact Dean, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified